Evidence map›Paper›PMID 37649530›Full record

ArticleOsteoarthritis and cartilage open2023

Development and validation of a machine learning-supported strategy of patient selection for osteoarthritis clinical trials: the IMI-APPROACH study.

Paweł Widera, Paco M J Welsing, Samuel O Danso, Sjaak Peelen, Margreet Kloppenburg, Marieke Loef, Anne C Marijnissen, Eefje M van Helvoort, Francisco J Blanco, Joana Magalhães and 11 more

Abstract read
In one paragraph

Article in Osteoarthritis and cartilage open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Paweł WideraSchool of Computing, Newcastle University, Newcastle, UK.
Paco M J WelsingDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Samuel O DansoSchool of Computing, Newcastle University, Newcastle, UK.
Sjaak PeelenLygature, Utrecht, the Netherlands.
Margreet KloppenburgDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Marieke LoefDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Anne C MarijnissenDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Eefje M van HelvoortDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Francisco J BlancoInstitute of Biomedical Research, University Hospital of A Coruña, A Coruña, Spain.
Joana MagalhãesInstitute of Biomedical Research, University Hospital of A Coruña, A Coruña, Spain.
Francis BerenbaumAPHP Hospital Saint-Antoine, Paris, France.
Ida K HaugenDivision of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Anne-Christine Bay-JensenNordic Bioscience, Herlev, Denmark.
Ali MobasheriDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Christoph LadelBioBone B.V., Amsterdam, Netherlands.
John LoughlinBioscience Institute, Newcastle University, International Centre for Life, Newcastle, UK.
Floris P J G LafeberDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Agnès LalandeServier International Research Institute, Suresnes, France.
Jonathan LarkinNovel Human Genetics Research Unit, GlaxoSmithKline, Collegeville, United States.
Harrie WeinansDepartment of Orthopedics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Jaume BacarditSchool of Computing, Newcastle University, Newcastle, UK.

Funding

Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

Objectives: To efficiently assess the disease-modifying potential of new osteoarthritis treatments, clinical trials need progression-enriched patient populations. To assess whether the application of machine learning results in patient selection enrichment, we developed a machine learning recruitment strategy targeting progressive patients and validated it in the IMI-APPROACH knee osteoarthritis prospective study. Design: We designed a two-stage recruitment process supported by machine learning models trained to rank candidates by the likelihood of progression. First stage models used data from pre-existing cohorts to select patients for a screening visit. The second stage model used screening data to inform the final inclusion. The effectiveness of this process was evaluated using the actual 24-month progression. Results: From 3500 candidate patients, 433 with knee osteoarthritis were screened, 297 were enrolled, and 247 completed the 2-year follow-up visit. We observed progression related to pain ( Conclusions: The machine learning-supported recruitment resulted in enriched selection of progressive patients. Further research is needed to improve structural progression prediction and assess this strategy in an interventional trial.

Indexed as

Disease progression predictionInclusionMachine learningOsteoarthritisPatient selection for clinical trials

Identifiers

PMID37649530
PMCPMC10463256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.